Taconic Biosciences and Cellaria Biosciences collaborate to facilitate xenograft use in oncology research

30-Mar-2015 - USA

Taconic Biosciences and Cellaria Biosciences announced that the two companies have entered into a scientific collaboration designed to facilitate and improve the utility of patient-derived xenografts (PDXs) in animal models for oncology and immuno-oncology research. Cellaria’s methodologies for generating cells from patient tumors will complement Taconic’s portfolio of tissue humanized mouse models, which are well-suited as hosts for PDXs.

The value of using patient-derived tumors in oncology and immuno-oncology research has been well documented, but traditional methods of obtaining tumor cell material have proven labor-intensive and expensive, inhibiting researchers’ access to this material. Cellaria’s approach to propagating tumor cell material and generating PDX banks significantly reduces the associated labor and costs, making patient-derived tumor models more accessible to investigators.  

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...